Biotech News
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Fully resolves all six ongoing lawsuits between the companies Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH) Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation
